Primary Job Title CEO Primary Organization 
Gene Predictis
Location Lausanne, Vaud, Switzerland Regions Europe, Middle East, and Africa (EMEA) Gender Female
LinkedIn View on LinkedIn
Dr Tanackovic obtained MSc degree in both Biology and Chemistry from the University of Osijek, Croatia. She then studied human hereditary disorders and, in 1999, earned PhD in Biology from the University of Zagreb, Croatia. In 2000 she moved to Geneva, Switzerland, where she worked in the filed of RNA research and was awarded her second PhD in
Biology in 2004, from the University of Geneva. Her postdoctoral research at the University of Lausanne was focused on molecular mechanisms involved in various genetic diseases. During her academic career, Dr Tanackovic successfully led various research projects, obtained numerous research grants, and results of her work are recognized through the publications in high-impact per-reviewed journals.
In parallel with her PhD studies, Dr Tanackovic successfully completed entrepreneurship program of “Create” Switzerland (2002) and was one of the winners of “Venture Leaders” program in 2003. In this frame, she also successfully completed an entrepreneurship program at Babson College, Wellesley, US (2003).
She joined Gene Predictis at the CEO position in September 2011. Over the past five years, she changed the vision and the strategy of the company with the buy-in of the board and the team. She recruited and built highly performing team committed to the new vision and strategy; the team doubled over the past five years. The custumer base grew to over 100 fidelized clients over the same period of time and sales of genetic tests increase with an annual growth rate of 50% per year. Under her guidance, the company developed new products of strategic interest for company, notably Pill Protect® and Nutripass®, as well as reached set strategic milestones for the company development and recruited the first strategic investor. Combining her strong entrepreneurial spirit and her experience, Dr Tanackovic is determined to further develp Gene Predictis and make company’s proprietary tests become benchmark to tailor drug therapies based on the individual.
